Atypical antipsychotic drugs and pregnancy outcome: A prospective, cohort study

Journal of Clinical Psychopharmacology

Volumn 33, Issue 4, 2013, Pages 453-462

  Habermann, Frank ^a   Fritzsche, Juliane ^a   Fuhlbrück, Frederike ^b   Wacker, Evelin ^a   Allignol, Arthur ^c,d   Weber Schoendorfer, Corinna ^a   Meister, Reinhard ^b   Schaefer, Christof ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

antipsychotics; fetal outcome; malformations; postnatal disorders; pregnancy

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; LITHIUM; MELPERONE; MIRTAZAPINE; QUETIAPINE; VENLAFAXINE;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; CONGENITAL MALFORMATION; DEPRESSION; FEMALE; FIRST TRIMESTER PREGNANCY; FOLLOW UP; HUMAN; LIVE BIRTH; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; NEWBORN DEATH; NEWBORN INTENSIVE CARE; OBSERVATIONAL STUDY; PATENT DUCTUS ARTERIOSUS; PERINATAL PERIOD; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHIATRIC TREATMENT; SCHIZOPHRENIA; SPONTANEOUS ABORTION; STILLBIRTH; TREATMENT INDICATION;

ABNORMALITIES, DRUG-INDUCED; ABORTION, INDUCED; ABORTION, SPONTANEOUS; ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; FEMALE; GESTATIONAL AGE; HUMANS; INFANT; INFANT MORTALITY; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; LOGISTIC MODELS; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; RISK ASSESSMENT; RISK FACTORS; STILLBIRTH; TREATMENT OUTCOME;

EID: 84879841153     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318295fe12     Document Type: Article

References (42)

1. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66:444-449.
2. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol. 2000;20: 399-403.
3. Shechtman S, Sharon E, Diav-Citrin O, et al. Pregnancy outcome after in-utero exposure to risperidone: a prospective controlled cohort study. 20th Annual Meeting of the European Network of Teratology Information Services (ENTIS); Florence, May 29, 2009.
4. Garayt C, Merieux C, Carlier C, et al. Pregnancy outcome in women exposed to atypical antipsychotics. 20th Annual Meeting of the European Network of Teratology Information Services (ENTIS); Florence, May 29, 2009.
5. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract. 2009;15:183-192.
6. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull. 2010;36:518-544.
7. McCauley-Elsom K, Gurvich C, Elsom SJ, et al. Antipsychotics in pregnancy. J Psychiatr Ment Health Nurs. 2010;17:97-104.
8. Trixler M, Gati A, Fekete S, et al. Use of antipsychotics in the management of schizophrenia during pregnancy. Drugs. 2005;65: 1193-1206.
9. Wichman CL. Atypical antipsychotic use in pregnancy: a retrospective review. Arch Womens Ment Health. 2009;12:53-57.
10. Paulus W, Schloemp S, Sterzik K, et al. Atypical antipsychotic agents in early pregnancy [abstract]. Reprod Toxicol. 2005;20:477.
11. Reis M, Källén B. Maternal use of antipsychotic in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28:279-288.
12. Diav-Citrin O, Shechtman S, Ornoy S, et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry. 2005;66:317-322.
13. Sexson WR, Barak Y. Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. J Perinatol. 1989;9: 170-172.
14. Mohan MS, Patole SK, Whitehall JS. Severe hypothermia in a neonate following antenatal exposure to haloperidol. J Paediatr Child Health. 2000;36:412-413.
15. Collins KO, Comer JB. Maternal haloperidol therapy associated with dyskinesia in a newborn. Am J Health Syst Pharm. 2003;60:2253-2255.
16. Coppola D, Russo LJ, Kwarta RF Jr, et al. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf. 2007;30:247-264.
17. Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164:1214-1220.
18. FDA Drug Safety Communication: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns; March 29, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ ucm243903.htm. Accessed August 27, 2012.
19. Matevosyan NR. Pregnancy and postpartum specifics in women with schizophrenia: a meta-study. Arch Gynecol Obstet. 2011;283:141-147.
20. Lin HC, Chen IJ, Chen YH, et al. Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophr Res. 2010;116:55-60.
21. Newham JJ, Thomas SH, MacRitchie K, et al. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry. 2008;192:333-337.
22. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296.
23. Schaefer C, Ornoy A, Clementi M, et al. Using observational cohort data for studying drug effects on pregnancy outcomeVmethodological considerations. Reprod Toxicol. 2008;26:36-41.
24. Schaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancyV15 years experience of ENTIS. Reprod Toxicol. 2005;20:331-343.
25. Eurocat malformation coding guide: clinical definition of subgroups; 2007. Available at: http://www.eurocat-network.eu/content/EUROCAT-Clinical- Definitions-Subgroups.pdf. Accessed August 27, 2012.
26. Rasmussen SA, Olney RS, Holmes LB, et al. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol. 2003;67:193-201.
27. Merks JH, van Karnebeek CD, Caron HN, et al. Phenotypic abnormalities: terminology and classification. Am J Med Genet A. 2003;123A:211-230.
28. The European Commission. VOLUME 9A of The Rules Governing Medicinal Products in the European Union. Guidelines on Pharmacovigilance for Medicinal Products for Human Use; September, 2008. Available at: http://ec.europa.eu/ health/files/eudralex/vol-9/pdf/vol9a-09-2008-en.pdf. Accessed August 27, 2012.
29. Källén B. Epidemiology of Human Reproduction. Boca Raton, Fla: CRC Press, Inc; 1988.
30. Meister R, Schaefer C. Statistical methods for estimating the probability of spontaneous abortion in observational studiesVanalyzing pregnancies exposed to coumarin derivatives. Reprod Toxicol. 2008; 26:31-35.
31. Udechuku A, Nguyen T, Hill R, et al. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry. 2010;44:978-996.
32. Sacker A, Done DJ, Crow TJ. Obstetric complications in children born to parents with schizophrenia: a meta-analysis of case-control studies. Psychol Med. 1996;26:279-287.
33. Bennedsen BE, Mortensen PB, Olesen AV, et al. Preterm birth and intra-uterine growth retardation among children of women with schizophrenia. Br J Psychiatry. 1999;175:239-245.
34. Hoffman JIL, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890-1900.
35. Lindinger A, Schwedler G, Hense HW. Prevalence of congenital heart defects in newborns in Germany: results of the first registration year of the PAN Study (July 2006 to June 2007). Klin Padiatr. 2010;222: 321-326.
36. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther. 2007;29:918-926.
37. Jablensky AV, Morgan V, Zubrick SR, et al. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry. 2005; 162:79-91.
38. Hizkiyahu R, Levy A, Sheiner E. Pregnancy outcome of patients with schizophrenia. Am J Perinatol. 2010;27:19-23.
39. Schneid-Kofman N, Sheiner E, Levy A. Psychiatric illness and adverse pregnancy outcome. Int J Gynaecol Obstet. 2008;101:53-56.
40. Martinez-Frias ML, Rodriguez-Pinilla E. Problems of using data from Teratology Information Services (TIS) to identify putative teratogens. Teratology. 1999;60:54-55.
41. Ornoy A, Mastroiacovo P. More on data from teratogen information systems (TIS). Teratology. 2000;61:327-328.
42. Johnson KA, Weber PA, Jones KL, et al. Selection bias in Teratology Information Service pregnancy outcome studies. Teratology. 2001; 64:79-82.